title: [Immunoglobulin deficiency after repeated plasmapheresis].
abstract: In 10 patients with Guillain-Barré syndrome the level of globulins and immunoglobulins before and after plasmapheresis was investigated. As a plasma substitute either PPL (in 8 patients) or a plasma substitute solution rich in immunoglobulins (in 2 patients) was used. When plasma was substituted with PPL, the globulins and immunoglobulins dropped to a mean of 40% of the initial value (range 30-60%) after the first plasmapheresis. With daily or alternate day plasmapheresis, the globulins only partially recovered. Before the second plasmapheresis they were still reduced to a mean of 50% (range 20-50%), and dropped further with ongoing exchanges to a mean of 33% (range 20-50%) as measured before the third plasmapheresis. Accordingly, there was a loss of immunoglobulins of similar magnitude. With the use of a plasma substitute solution rich in immunoglobulins (IRP), globulins could be maintained at normal levels. The lowest immunoglobulin values measured after plasmapheresis were 6 g/l (normal range 8-17 g/l). One patient developed gram-negative septicaemia after plasmapheresis with PPL, possibly due to a low immunoglobulin concentration. We conclude that a plasma substitute solution rich in immunoglobulins should be used for therapeutic plasmapheresis in order to maintain physiological immunoglobulin concentrations.
authors.affiliation: Departement Innere Medizin, Kantonsspital Basel.
authors.forename: C
authors.initials: C
authors.lastname: Stebler
authors.forename: A
authors.initials: A
authors.lastname: Tichelli
authors.forename: H
authors.initials: H
authors.lastname: Dazzi
authors.forename: M
authors.initials: M
authors.lastname: Wernli
authors.forename: A
authors.initials: A
authors.lastname: Gratwohl
authors.forename: B
authors.initials: B
authors.lastname: Speck
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage / Q000172:deficiency; D007153:Immunologic Deficiency Syndromes / Q000209:etiology* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D010952:Plasma Substitutes / Q000008:administration & dosage; D010956:Plasmapheresis / Q000009:adverse effects*; D011129:Polyradiculoneuropathy / Q000628:therapy*
chemical_list: D007136:Immunoglobulins; D010952:Plasma Substitutes